TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

TXG shares dropped more than 5% despite securing a $4.8 million jury verdict against Parse Biosciences, a subsidiary of QGEN, for willful patent infringement. The jury upheld the validity of all three 10x Genomics single-cell analysis patents and found Parse liable for infringement.

The company plans to pursue enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings, which could expand the financial and operational impact beyond the initial $4.8 million award. The enhanced damages motion, typical in willful infringement cases, could multiply the base award.

The market's negative reaction suggests investors view the initial damages as modest relative to legal costs or see limited commercial impact from a Parse injunction. TXG's single-cell sequencing business faces competition from multiple players including QGEN, and the verdict addresses only one competitor's product line.